This Medical Product Alert relates to confirmed falsified versions of ICLUSIG 15mg and ICLUSIG 45mg circulating in the WHO Region of Europe and the WHO Region of the Americas. Genuine ICLUSIG, the active pharmaceutical ingredient of which is Ponatinib Hydrochloride, is used to treat different forms of leukaemia.
On 15 January 2019, WHO was informed by health authorities in Switzerland that a local wholesaler had purchased packs of ICLUSIG 15mg : upon verification, the market authorization holder confirmed these packs as falsified. Further investigation confirmed that there are two versions of falsified ICLUSIG being traded globally, including via internet sales, detailed in the below table:
Enfermedades denominadas de Creutzfeldt-Jakob no se transmiten de persona a persona, por contacto cercano o por gotitas de saliva.
30 de enero 2019. La enfermedad de Creutzfeldt-Jakob (ECJ) es una enfermedad neurológica con formas genéticas hereditarias, producidas por una variante llamada prion (PrP), provoca trastornos neurológicos progresivos…
A minuta do documento será apresentada em reunião nesta quinta-feira (31/1), em Brasília. Guia deve orientar empresas na elaboração de dossiê técnico-científico.
